|
|
 |
 |
|
|
 |
|
|
|
VaxGen's AIDS vaccine for developing world shows unexpected activity Source: VaxGen, Inc BRISBANE, Calif., June 26 -- VaxGen, Inc. (Nasdaq: VXGN) presented laboratory data today at an international scientific conference indicating that antibodies to HIV subtype C (HIV-C) have an unexpected ability to bind to significant regions of another HIV subtype. The findings indicate that a vaccine that induces HIV-C antibodies may be effective at preventing infection not only by HIV-C but by other subtypes as well. HIV-C causes half of the world''''s HIV infections and is the predominant subtype in southern Africa, India and China. VaxGen also described a new trivalent formulation of its vaccine, AIDSVAX, which is designed to prevent infection by three of the world''''s five major HIV subtypes, including HIV-C. The development of this formulation, which has yet to be tested in human clinical trials, furthers the company''''s goal of tailoring vaccines to target specific HIV subtypes and strains in various geographic regions.
—Posted: June 26, 2001
More news headlines: This week | Last week | Search archive
|
|
|
